Comparative evaluation of the efficacy and safety of surgical methods for the treatment of benign prostatic hyperplasia: bipolar TURP and ThuLEP

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To improve surgical outcomes in patients with benign prostatic hyperplasia (BPH) by assessing the efficacy and safety of bipolar transurethral resection of the prostate (b-TURP) in comparison with thulium laser enucleation of the prostate (ThuLEP).

Materials and methods. A retrospective and prospective analysis of surgical outcomes was performed in 555 patients with BPH who were examined and operated on between 2018 and 2024. Among them, 301 patients underwent bipolar TURP, and 254 patients underwent transurethral thulium laser enucleation of the prostate (ThuLEP). The mean age of patients was 68.8±8.10 years in the b-TURP group and 68.3±8.10 years in the ThuLEP group (p>0.05).

Results. The intraoperative blood loss and volume of removed tissue were significantly higher in the ThuLEP group. The incidence of early and late postoperative complications was significantly higher in patients after b-TURP. The need for additional postoperative pharmacotherapy and its duration due to lower urinary tract symptoms (LUTS) were also significantly greater after b-TURP.

Conclusion. Although both techniques provide a comparable and high efficacy in the surgical removal of adenomatous prostatic tissue, their safety profiles differ. Despite effective relief of bladder outlet obstruction, bipolar TURP is inferior to ThuLEP in terms of patient safety and early postoperative recovery.

Full Text

Restricted Access

About the authors

Furkat R. Nasirov

Republican Specialized Scientific and Practical Medical Center of Urology

Email: nosirovfurkat5@gmail.com
ORCID iD: 0009-0009-6868-625X

Ph.D., MD, Senior Researcher, Head of the Scientific Laboratory

Uzbekistan, Tashkent

Khusan T. Valiev

Fergana Institute of Public Health

Email: valievhusan10@gmail.com
ORCID iD: 0009-0004-3345-6001

assistant at the Department of Urology and Oncology, Fergana Institute of Public Health. Address: 2A Yangi Turon Street, Fergana, 150100, Uzbekistan. E-mail: valievhusan10@gmail.com. ORCID: https://orcid.org/0009-0004-3345-6001 

Uzbekistan, Fergana

Fayzulla Y. Yuldashev

Fergana Institute of Public Health

Email: fy.doctor@mail.ru
ORCID iD: 0009-0006-3457-6528

Ph.D., MD, Professor, Vice-Rector for Clinical Affairs

Uzbekistan, Fergana

Shukhrat I. Giyasov

Republican Specialized Scientific and Practical Medical Center of Urology; Tashkent State Medical University

Author for correspondence.
Email: dr.sh.giyasov@gmail.com
ORCID iD: 0000-0002-1558-3443

Ph.D., MD, Professor, Department of Urology, Tashkent State Medical University; Consultant, Republican Specialized Scientific and Practical Medical Center of Urology

Uzbekistan, Tashkent; Tashkent

References

  1. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr, Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019 Oct;8(5):529-539. doi: 10.21037/tau.2019.10.01. PMID: 31807429; PMCID: PMC6842780.
  2. Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA. Members of the Florey Adelaide Male Ageing Study. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011 Apr;29(2):179-84. doi: 10.1007/s00345-010-0605-8. Epub 2010 Oct 21. PMID: 20963421.
  3. Soci t Internationale d’Urologie (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS. C. Chapple & P. Abrams, Editors.2013.https://www.siu-rology.org/themes/web/assets/files/ICUD/pdf/Male%20Lower%20Urinary%20Tract%20 Symptoms%20(LUTS).pdf
  4. Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006 Jul;7(4):272-81. doi: 10.1007/s11934-996-0006-0. PMID: 16930498.
  5. EAU Guidelines 2024. EAU Guidelines on non-neurogenic male LUTS including Benigh Prostatic Obstruction. P.184-208
  6. Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 2010 Feb;28(1):45-51. doi: 10.1007/s00345-009-0503-0. PMID: 20063164.
  7. Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ. Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol. 2009 Aug;27(4):541-5. doi: 10.1007/s00345-008-0370-0. Epub 2009 Jan 28. PMID: 19184038.
  8. Enikeev D.V. Comparative analysis of leading modern surgical methods of treatment of prostate hyperplasia. Diss. for the degree of Doctor of Medical Sciences. M., 2018. 227 p. Russian (Еникеев Д.В. Сравнительный анализ ведущих современных оперативных методик лечения гиперплазии простаты. Дисс. на соиск. уч. ст. д.м.н. M., 2018 г. 227 c.).
  9. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008 Jul;180(1):246-9. doi: 10.1016/j.juro.2008.03.058. Epub 2008 May 21. PMID: 18499179.
  10. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015 Jun;67(6):1066-1096. doi: 10.1016/j.eururo.2014.06.017. Epub 2014 Jun 25. PMID: 24972732.
  11. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur Urol. 2006 Nov;50(5):969-79; discussion 980. doi: 10.1016/j.eururo.2005.12.042. Epub 2006 Jan 30. PMID: 16469429.
  12. Giyasov Sh.I., Gafarov R.R., Shodmonova Z.R., Mukhtarov Sh.T., Akilov F.A. The Role of Systematization of Postoperative Complications in Assessing the Effectiveness and Safety of Surgical Methods for the Treatment of Benign Prostatic Hyperplasia. Urologiia. 2022;3:83–91. Russian (Гиясов Ш.И., Гафаров Р.Р., Шодмонова З.Р., Мухтаров Ш.Т., Акилов Ф.А. Роль систематизации послеоперационных осложнений в оценке эффективности и безопасности хирургических методов лечения доброкачественной гиперплазии предстательной железы. Урология. 2022;3:83–91).
  13. Gafarov R.R. Optimization of Surgical Treatment Tactics for Benign Prostatic Hyperplasia. Dissertation for the Degree of Doctor of Philosophy (PhD) in Medicine. 2022. 120 p. Russian (Гафаров Р.Р. Оптимизация тактики хирургического лечения доброкачественной гиперплазии предстательной железы. Диссертация на соискание ученой степени доктора философии (PhD) по медицине. 2022. 120 с.).
  14. Akilov F.A., Giyasov Sh.I., Mukhtarov Sh.T., Nasirov F.R. Alidjanov J.F. Applicability of the Clavien-Dindo grading system for assessing the postoperative complications of endoscopic surgery for nephrolithiasis: a critical review. Turkish Journal of Urology. 2013;39(3):153–60. doi: 10.5152/tud.2013.032.
  15. Chughtai B, Simma-Chiang V, Kaplan SA. Evaluation and management of post-transurethral resection of the prostate lower urinary tract symptoms. Curr Urol Rep. 2014 Sep;15(9):434. doi: 10.1007/s11934-014-0434-1. PMID: 25037906.
  16. Kim SJ, Al Hussein Alawamlh O, Chughtai B, Lee RK. Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. Curr Urol Rep. 2018 Aug 20;19(10):85. doi: 10.1007/s11934-018-0838-4. PMID: 30128964.
  17. Campbell RA, Gill BC. Medication Discontinuation Following Transurethral Prostatectomy: an Unrecognized Effectiveness Measure? Curr Urol Rep. 2020 Nov 7;21(12):61. doi: 10.1007/s11934-020-01015-9. PMID: 33159617.
  18. Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, Byun SS, Kim SI, Jung TY. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014 Sep;84(3):675-80. doi: 10.1016/j.urology.2014.04.027. Epub 2014 Jul 22. PMID: 25059592.
  19. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19. PMID: 25613154.
  20. Huang SW, Tsai CY, Tseng CS, Shih MC, Yeh YC, Chien KL, Pu YS, Tu YK. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ. 2019 Nov 14;367:l5919. doi: 10.1136/bmj.l5919. PMID: 31727627; PMCID: PMC7223639.
  21. Zhang Y, Yuan P, Ma D, Gao X, Wei C, Liu Z, Li R, Wang S, Liu J, Liu X. Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):493-508. doi: 10.1038/s41391-019-0135-4. Epub 2019 Feb 28. PMID: 30816336.
  22. Shoji S, Hanada I, Otaki T, Ogawa T, Yamada K, Uchida T, Higure T, Kawakami M, Kim H, Nitta M, Hasegawa M, Kawamura Y, Miyajima A. Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: A prospective randomized study. Int J Urol. 2020 Nov;27(11):974-980. doi: 10.1111/iju.14341. Epub 2020 Aug 16. PMID: 33241599.
  23. Strope SA, Vetter J, Elliott S, Andriole GL, Olsen MA. Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Urology. 2015 Dec;86(6):1115-22. doi: 10.1016/j.urology.2015.07.019. Epub 2015 Sep 12. PMID: 26375848; PMCID: PMC4698045.
  24. Campbell J, Reid J, Ordon M, Welk B. The Utilization of Benign Prostatic Hyperplasia and Bladder-Related Medications After a Transurethral Prostatectomy. Urology. 2019 Aug;130:126-131. doi: 10.1016/j.urology.2019.05.003. Epub 2019 May 23. PMID: 31129193.
  25. Sabharwal NC, Shoskes DA, Dielubanza EJ, Ulchaker JC, Fareed K, Gill BC. Comparative Effectiveness of Transurethral Prostate Procedures at Enabling Urologic Medication Discontinuation: A Retrospective Analysis. Urology. 2019 Dec;134:192-198. doi: 10.1016/j.urology.2019.07.039. Epub 2019 Sep 19. PMID: 31542460.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media